USPTO Rejects ATAI Life Sciences’ Ibogaine Co-Administration Patent Application: Implications and Insights
The application for patent 17/941,648 bu ATAI Life Sciences is being disapproved at non-final stage by the United States Patent and Trademark Office (USPTO). Their proposed combination treatment involving co-administration of Ibogaine with a metabolism inhibitor was intended to create safer psychotropic therapies. Porta Sophia, a non-profit organization dedicated to creating an ethical and equitable […]